The role of Toll-like receptor 4 polymorphisms in vaccine immune response

Pharmacogenomics Journal

Volumn 16, Issue 1, 2016, Pages 96-101

  Pellegrino, P ^a   Falvella, F S ^a   Cheli, S ^a   Perrotta, C ^a   Clementi, E ^a,b   Radice, S ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR 4; TUMOR ANTIGEN PRESENTING CELL VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; VACCINE;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; AGED; CAUCASIAN; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MEASLES; MENINGOCOCCOSIS; PERTUSSIS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TLR4 GENE; VACCINATION; ANIMAL; GENETICS; IMMUNOLOGY; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; HUMANS; MEASLES VACCINE; MENINGOCOCCAL VACCINES; PERTUSSIS VACCINE; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTOR 4; VACCINES;

EID: 84956800734     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.21     Document Type: Review

References (87)

1. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95.
2. Takeda K, Akira S. Toll-like receptors. In:Coligan JE et al. (eds). Current Protocols in Immunology, Chapter 14, Unit 14 12, 2007.
3. Imler JL, Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol 2001; 11: 304-311.
4. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397.
5. Medzhitov R, Janeway C Jr. Innate immunity. New Engl J Med 2000; 343: 338-344.
6. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
7. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
8. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1 R signalling. Nature 2010; 465: 885-890.
9. McAleer JP, Vella AT. Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. Trends Immunol 2010; 31: 429-435.
10. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65: 3231-3240.
11. Noreen M, Shah MA, Mall SM, Choudhary S, Hussain T, Ahmed I et al. TLR4 polymorphisms and disease susceptibility. Inflamm Res 2012; 61: 177-188.
12. Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA. Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barre patients. J Neuroimmunol 2004; 150: 132-138.
13. Bank S, Skytt Andersen P, Burisch J, Pedersen N, Roug S, Galsgaard J et al. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish Cohort. PloS One 2014; 9: e98815.
14. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet 2005; 5: 156-164.
15. Balfour HH Jr., Edelman CK, Amren DP. Antibody response following customary use of MMR vaccine. JAMA 1984; 251: 3223-3224.
16. Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Exp Rev Vaccines 2013; 12: 57-70.
17. Li ZK, Nie JJ, Li J, Zhuang H. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 2013; 31: 4355-4361.
18. Pondo T CE Jr, Martin SW, Keitel WA, Keyserling HL, Babcock J et al. Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Vaccine 2014; 32: 3548-3554.
19. Klein SL, Poland GA. Personalized vaccinology: one size and dose might not fit both sexes. Vaccine 2013; 31: 2599-2600.
20. Haq K, McElhaney JE. Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol 2014; 29C: 38-42.
21. Pellegrino P, Carnovale C, Perrone V, Pozzi M, Antoniazzi S, Radice S et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. Vaccine 2014; 32: 4730-4735.
22. Delpeut S, Noyce RS, Siu RW, Richardson CD. Host factors and measles virus replication. Curr Opin Virol 2012; 2: 773-783.
23. Centers for Disease C, Prevention. Progress in reducing measles mortality - worldwide, 1999-2003. MMWR 2005; 54: 200-203.
24. Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics 2004; 5: 417-427.
25. Poland GA, Ovsyannikova IG, Jacobson RM. Personalized vaccines: the emerging field of vaccinomics. Exp Opin Biol Ther 2008; 8: 1659-1667.
26. Poland GA, Ovsyannikova IG, Jacobson RM. Vaccine immunogenetics: bedside to bench to population. Vaccine 2008; 26: 6183-6188.
27. Posteraro B, Pastorino R, Di Giannantonio P, Ianuale C, Amore R, Ricciardi W et al. The link between genetic variation and variability in vaccine responses: Systematic review and meta-analyses. Vaccine 2014; 32: 1661-1669.
28. Haralambieva IH, Salk HM, Lambert ND, Ovsyannikova IG, Kennedy RB, Warner ND et al. Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. Vaccine 2014; 32: 1946-1953.
29. Hahm B, Cho JH, Oldstone MB. Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. Virology 2007; 358: 251-257.
30. Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 2002; 76: 8729-8736.
31. Dhiman N, Ovsyannikova IG, Vierkant RA, Ryan JE, Pankratz VS, Jacobson RM et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008; 26: 1731-1736.
32. Ovsyannikova IG, Haralambieva IH, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum Genet 2011; 130: 547-561.
33. Guiso N. How to fight pertussis? Ther Adv Vaccines 2013; 1: 59-66.
34. Ausiello CM, Cassone A. Acellular pertussis vaccines and pertussis resurgence: revise or replace? mBio 2014; 5: e01339-14.
35. Fallo A, Manonelles G, Hozbor D, Lara C, Huespe M, Mazzeo S et al. Pertussis seroprevalence in adults, post-partum women and umbilical cord blood. Arch Argent Pediatr 2014; 112: 315-322.
36. Banus HA, Vandebriel RJ, de Ruiter H, Dormans JA, Nagelkerke NJ, Mooi FR et al. Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology. Infect Immun 2006; 74: 2596-2605.
37. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006; 177: 7980-7989.
38. Banus S, Bottema RW, Siezen CL, Vandebriel RJ, Reimerink J, Mommers M et al. Toll-like receptor 4 polymorphism associated with the response to whole-cell pertussis vaccination in children from the KOALA study. Clin Vaccine Immunol 2007; 14: 1377-1380.
39. Kimman TG, Banus S, Reijmerink N, Reimerink J, Stelma FF, Koppelman GH et al. Association of interacting genes in the toll-like receptor signaling pathway and the antibody response to pertussis vaccination. PloS One 2008; 3: e3665.
40. Grondahl-Yli-Hannuksela K, Vuononvirta J, Barkoff AM, Viander M, Van Der Meeren O, Mertsola J et al. Gene polymorphism in toll-like receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence. J Infect Dis 2012; 205: 1214-1219.
41. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27: B51-B63.
42. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50: S37-S44.
43. Pellegrino P, Perrone V, Radice S, Capuano A, Clementi E. Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: Systematic review and meta-analysis. Pharmacol Res 2014; 92C: 31-39.
44. Faber J, Meyer CU, Gemmer C, Russo A, Finn A, Murdoch C et al. Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. Pediatr Infect Dis J 2006; 25: 80-81.
45. Biebl A, Muendlein A, Kazakbaeva Z, Heuberger S, Sonderegger G, Drexel H et al. CD14 C-159 T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patients. PloS One 2009; 4: e7374.
46. Spector SA, Qin M, Lujan-Zilbermann J, Singh KK, Warshaw MG, Williams PL et al. Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCgamma receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth. Clin Vaccine Immunol 2013; 20: 900-906.
47. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50: 184-191.
48. Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Brusadelli T et al. Epidemiological analysis on two decades of hospitalisations for meningitis in the United States. Eur J Clin Microbiol Infect Dis 2014; 33: 1519-1524.
49. Moore CE, Hennig BJ, Perrett KP, Hoe JC, Lee SJ, Fletcher H et al. Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine. Clin Vaccine Immunol 2012; 19: 295-303.
50. Zughaier SM. Neisseria meningitidis capsular polysaccharides induce inflammatory responses via TLR2 and TLR4-MD-2. J Leukoc Biol 2011; 89: 469-480.
51. Fransen F, Stenger RM, Poelen MC, van Dijken HH, Kuipers B, Boog CJ et al. Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis. PloS One 2010; 5: e15692.
52. Alving CR. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 1993; 187: 430-446.
53. Johnson DA, Keegan DS, Sowell CG, Livesay MT, Johnson CL, Taubner LM et al. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J Med Chem 1999; 42: 4640-4649.
54. Baldridge JR, Cluff CW, Evans JT, Lacy MJ, Stephens JR, Brookshire VG et al. Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. J Endotoxin Res 2002; 8: 453-458.
55. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183: 6186-6197.
56. Tiberio L, Fletcher L, Eldridge JH, Duncan DD. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine 2004; 22: 1515-1523.
57. Newport MJ, Allen A, Awomoyi AA, Dunstan SJ, McKinney E, Marchant A et al. The toll-like receptor 4 Asp299Gly variant: no influence on LPS responsiveness or susceptibility to pulmonary tuberculosis in The Gambia. Tuberculosis 2004; 84: 347-352.
58. Long H, O'Connor BP, Zemans RL, Zhou X, Yang IV, Schwartz DA. The Toll-like receptor 4 polymorphism Asp299Gly but not Thr399Ile influences TLR4 signaling and function. PloS One 2014; 9: e93550.
59. Yamakawa N, Ohto U, Akashi-Takamura S, Takahashi K, Saitoh S, Tanimura N et al. Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A. Int Immunol 2013; 25: 45-52.
60. Sato K, Yoshimura A, Kaneko T, Ukai T, Ozaki Y, Nakamura H et al. A single nucleotide polymorphism in 3′-untranslated region contributes to the regulation of Toll-like receptor 4 translation. J Biol Chem 2012; 287: 25163-25172.
61. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426.
62. Escobar A, Lopez M, Serrano A, Ramirez M, Perez C, Aguirre A et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005; 142: 555-568.
63. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 2009; 27: 945-952.
64. Perrotta C, Bizzozero L, Falcone S, Rovere-Querini P, Prinetti A, Schuchman EH et al. Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res 2007; 67: 7559-7564.
65. Paolucci C, Rovere P, De Nadai C, Manfredi AA, Clementi E. Nitric oxide inhibits the tumor necrosis factor alpha -regulated endocytosis of human dendritic cells in a cyclic GMP-dependent way. J Biol Chem 2000; 275: 19638-19644.
66. Andrews DM, Maraskovsky E, Smyth MJ. Cancer vaccines for established cancer: how to make them better? Immunol Rev 2008; 222: 242-255.
67. Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol 2012; 91: 53-58.
68. Zaloudik J, Vagunda V, Drahokoupilova M, Janakova L, Talac R, Kalabis J et al. Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma. Int J Immunopharmacol 1997; 19: 481-485.
69. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999; 5: 178-186.
70. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005; 560: 11-18.
71. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect 2004; 6: 1382-1387.
72. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunology 2002; 2: 185-194.
73. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276: 37692-37699.
74. Tittarelli A, Gonzalez FE, Pereda C, Mora G, Munoz L, Saffie C et al. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother 2012; 61: 2067-2077.
75. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C et al. Trial Watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1: 699-716.
76. Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog 2011; 7: e1002344.
77. Davis RL. The vaccine adverse event reporting system and vaccine safety research in the genomics era. Vaccine 2012; 30: 1162-1164.
78. Pellegrino P, Falvella FS, Perrone V, Carnovale C, Brusadelli T, Pozzi M et al. The first steps towards the era of personalised vaccinology: predicting adverse reactions. Pharmacogenomics J 2014; doi:10.1038/tpj.2014.57 [e-pub ahead of print].
79. Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Brusadelli T et al. On the association between human papillomavirus vaccine and primary ovarian failure. Am J Reprod Immunol 2014; 71: 293-294.
80. Pellegrino P, Carnovale C, Perrone V, Antoniazzi S, Pozzi M, Clementi E et al. No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus. Eur J Epidemiol 2013; 28: 705-707.
81. Pellegrino P, Carnovale C, Perrone V, Pozzi M, Antoniazzi S, Clementi E et al. Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems. PloS One 2013; 8: e77766.
82. Pellegrino P, Carnovale C, Radice S, Clementi E. Influenza-like illness after yellow fever vaccination. J Clin Virol 2014; 60: 181.
83. Pellegrino P, Carnovale C, Perrone V, Antoniazzi S, Pozzi M, Clementi E et al. Can HPV immunisation cause ADEM? Two case reports and literature review. Mult Scler 2014; 20: 762-763.
84. Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Brusadelli T et al. On the possible interaction between vaccines and drugs. Eur J Clin Pharmacol 2014; 70: 369-371.
85. Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014; 13: 736-741.
86. Reif DM, McKinney BA, Motsinger AA, Chanock SJ, Edwards KM, Rock MT et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis 2008; 198: 16-22.
87. Pellegrino P, Perrone V, Pozzi M, Carnovale C, Perrotta C, Clementi E et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res 2014; 61: 90-96.